KCNN4 and glioblastoma: Pharmacological in-vitro studies show that inhibition of KCa3.1 channel activity suppresses proliferation of pancreatic cancer [17] and hepatocellular carcinoma cells [11], reduces cell motility in glioblastoma [10], and also reduces endothelial cell proliferation and neo-angiogenesis on matrigels [20].